Phase II Trial of hOKT3gamma1(Ala-Ala) Teplizumab for Treatment of Patients With Recent Onset Type 1 Diabetes.

Trial Profile

Phase II Trial of hOKT3gamma1(Ala-Ala) Teplizumab for Treatment of Patients With Recent Onset Type 1 Diabetes.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Teplizumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms DELAY
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jul 2012 Status changed from active, no longer recruiting to completed, based on results presented at ADA.
    • 12 Jun 2012 Final results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top